17:24 , Sep 14, 2018 |  BC Week In Review  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
22:43 , Sep 13, 2018 |  BC Week In Review  |  Company News

Zealand brings in $205M for pipeline via royalty pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million. Sanofi...
22:19 , Sep 13, 2018 |  BC Extra  |  Company News

Sanofi creating China/emerging markets and primary care units

Sanofi (Euronext:SAN; NYSE:SNY) said it will create two new global business units early next year, one focused on China and emerging markets and the other on primary care. The China and emerging markets unit will be...
23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
18:30 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Sanofi's Cablivi gains EU approval, Priority Review in U.S.

Sanofi (Euronext:SAN; NYSE:SNY) said the European Commission approved Cablivi caplacizumab to treat rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP). The company also revealed Sept. 3 that FDA accepted and granted Priority Review to...
17:36 , Sep 7, 2018 |  BC Week In Review  |  Company News

MannKind stock climbs after closing treprostinil deal with United Therapeutics

MannKind Corp. (NASDAQ:MNKD; Tel Aviv:MNKD) shot up $0.98 (89%) to $2.08. on Sept. 4 after signing a deal with United Therapeutics Corp. (NASDAQ:UTHR) for rights to Treprostinil Technosphere. MannKind will receive $45 million up front...
23:38 , Sep 6, 2018 |  BC Extra  |  Company News

Zealand brings in $205M for pipeline via Royalty Pharma deal

Zealand Pharma A/S (CSE:ZEAL; NASDAQ:ZEAL) said it will sell royalty rights and $85 million in potential commercial milestones tied to diabetes drugs Soliqua/Suliqua and Lyxumia/Adlyxin lixisenatide to Royalty Pharma (New York, N.Y.) for $205 million....
11:04 , Sep 5, 2018 |  BioCentury  |  Finance

Fulcrum’s genetic levers

Fulcrum Therapeutics Inc.’s ability to identify targets for genetic disease drivers using bioinformatics prompted Foresite Capital to lead the company’s untranched $80 million series B round. Fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital,...
11:02 , Sep 5, 2018 |  BC Extra  |  Financial News

Fulcrum raises $80M series B

Fulcrum Therapeutics Inc. (Cambridge, Mass.) raised $80 million in an untranched series B round led by Foresite Capital. Also participating were fellow new investors Fidelity, 6 Dimensions Capital, Casdin Capital, Sanofi Venture, Section 32, NS...
00:07 , Sep 5, 2018 |  BC Extra  |  Company News

Management tracks: Agios, Radius

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said David Schenkein will step down as CEO and become executive chairman, effective Feb. 1, 2019. He will succeed Chairman John Maraganore, who is also CEO at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY)....